関連する実験動画

Updated: May 5, 2026

A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation

A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation

Published on: July 13, 2018

加速されたミトコンドリアアデノシン二酸化酸/アデノシン三酸化酸輸送は高血圧による心臓病を改善する

Thomas Walther¹, Carsten Tschöpe, Anja Sterner-Kock

¹Charité-Universitätsmedizin, Campus Benjamin Franklin, Department of Cardiology and Pneumonology, Hindenburgdamm 30, 12200 Berlin, Germany. thomas.walther@charite.de

|January 11, 2007

まとめ

心臓におけるアデニンヌクレオチドトランスロカゼ1 (ANT1) の過剰発現は,ミトコンドリアの機能を改善し,高血圧による心臓機能不全から保護します. これは,ミトコンドリアのエネルギー伝達の強化が心臓病の治療のための有望な戦略であることを示唆しています.

科学分野:

心血管生物学心血管生物学
ミトコンドリア医学とは
分子心臓病学分子心臓病学

背景:

ミトコンドリアの機能障害はエネルギー代謝を乱し,アポトーシスを促進し,心不全を引き起こす.
アデニンヌクレオチドトランスロカゼ (ANT) は,内部のミトコンドリア膜を介してATP / ADP交換を通じて細胞のエネルギー供給に不可欠です.

研究の目的:

強化されたミトコンドリアのATP/ADP輸送が心臓機能不全に与える影響を調査する.
高血圧のラットモデルにおける心臓特異的なANT1過剰発現の心臓保護効果を評価する.

主な方法:

心臓でANT1を過剰発現するトランス遺伝子マウスを生成した.
ANT1過剰発現のラットとレニン過剰発現のラット (高血圧モデル) を交差させた.
心臓機能,ミトコンドリア活性,アポトーシスマーカー,組織構造を評価した.

主要な成果:

心臓のANT1過剰発現はATP/ADP輸送と呼吸器連鎖複合体の活動を増大させた.
ANT1は高血圧に起因する心筋縮を予防し,左心室の機能を改善しました.
線維症の減少,心臓組織構造の改善,および生存の増加は,ANT/RENラットで観察されました.
ミトコンドリアの構造と機能が改善され,ANT/RENラットのアポトーシスが著しく減少しました.

結論:

心筋のANT1過剰発現は,高血圧による心臓病変に対する保護を提供します.
ミトコンドリア機能の改善は,新しい心臓病の治療戦略の基本的な原則です.

さらに関連する動画

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

Author Spotlight: New Insights into PBMC Mitochondrial Responses Using Fluorespirometry

Author Spotlight: New Insights into PBMC Mitochondrial Responses Using Fluorespirometry

Published on: May 24, 2024

関連する概念動画

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

ATP Synthase: Mechanism

ATP Synthase: Mechanism

In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...

The ADP/ATP Carrier Protein

The ADP/ATP Carrier Protein

ADP/ATP carrier or AAC protein is the most abundant carrier protein in the inner mitochondrial membrane. It transports large quantities of ADP and ATP, equivalent to the average human body weight, every day. Among other transporters, ACC protein is one of the best-studied members of the mitochondrial carrier protein family. The ADP/ATP carrier protein comprises two transmembrane helices connected to a loop and a single alpha-helix on the matrix side. It switches between two conformational...

Antihypertensive Drugs: Action of β1 Blockers

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...